A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)
Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: Neural Stem Cells
Eligibility
Inclusion Criteria:
- Age 18 - 75 years
- History of ischemic subcortical stroke in the middle cerebral artery and/or
lenticulostriate artery 6 to 60 months from time of stroke
- Ability of subject to understand and provide written Informed Consent
- Willing to take tacrolimus (Prograf) 2 days before and for 2 months after transplant
Exclusion Criteria:
- Stroke lesion less than 1 cubic centimeter or greater than 100 cubic centimeters
measured by MRI
- Index stroke is lacunar infarct less than 1 year old
- History or presence of any major neurological disease
- History of active cancer other than basal or squamous cell skin cancers
- History of seizures
- Pregnant or breast-feeding
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Clinical Research Coordinator
650-723-0508
I'm interested